Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
[dermatan sulfate]n = [dermatan sulfate]n-1 + 4-deoxy-beta-D-gluc-4-enuronosyl-1,3-GalNAc
[dermatan sulfate]n = [dermatan sulfate]n-1 + 4-deoxy-beta-D-gluc-4-enuronosyl-1,3-GalNAc
acts on dermatan sulfate as sole substrate, active site structure involving Lys250, Arg271, His272, and Glu333, substrate binding mechanism involving Arg363 and Arg364
[dermatan sulfate]n = [dermatan sulfate]n-1 + 4-deoxy-beta-D-gluc-4-enuronosyl-1,3-GalNAc
acts on dermatan sulfate as sole substrate, catalytic mechanism, Glu333 is involved, substrate binding mechanism involving Arg318 and Arg364 interacting with the sulfate group
[dermatan sulfate]n = [dermatan sulfate]n-1 + 4-deoxy-beta-D-gluc-4-enuronosyl-1,3-GalNAc
acts on dermatan sulfate as sole substrate, enzyme cleaves the beta(1,4)-linkage of dermatan sulfate in a random manner, yielding 4,5-unsaturated dermatan sulfate disaccharides, calcium-dependent catalytic mechanism, active site structure
[dermatan sulfate]n = [dermatan sulfate]n-1 + 4-deoxy-beta-D-gluc-4-enuronosyl-1,3-GalNAc
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
6-8 mg/ml purified recombinant enzyme, residues 25-506, in 20 mM Tris-HCl, pH 8.0, 1 mM sodium phosphate, pH 7.0, 3 mM NaCl, 0.5 mM phenylmethylsulfonyl fluoride, 0.001 mg/ml aprotinin, 0.001 mg/ml leupeptin, 0.001 mg/ml E64, hanging drop vapour diffusion method, 292 K, mixed with a double volume of reservoir solution containing 19% w/v PEG 8000, 100 mM bicine buffer, pH 9.0, or 100 mM Tris-HCl, pH 8.8, 0.15 M ammonium acetate, 15% v/v 2-methyl-2,4-pentanediol, drops are suspended over 1 ml of resevroir solution, crystals appear overnight, seeds are introduced into drops conisting of 0.002 ml protein solution, 6.1 mg/ml protein, and 0.004 ml reservoir solution containing 16.5% w/v PEG 8000, 0.1 M Tris-HCl, pH 8.8, 15% v/v 2-methyl-2,4-pentanediol, 0.25 M ammonium acetate, 292 K, 2-3 weeks, X-ray diffraction structure determination and analysis at 2.20-2.28 A resolution
purified recombinant enzyme, residues 25-506 corresponding to the full size mature enzyme, labeling and complexing of enzyme in crystals via soaking in cryoprotectant solution containing the heavy atom or disaccharide product in 22.5% w/v PEG 8000, 0.1 M Tris-HCl, pH 8.7, 15% v/v 2-methyl-2,4-pentanediol, and 0.25 M ammonium acetate, equilibration over 1 ml reservoir solution, complexed with disaccharide product, X-ray diffraction structure determination and analysis at 1.7 A resolution, structure modeling of the right-handed parallel beta-helix protein
purified recombinant wild-type enzyme complexed with dermatan sulfate pentasaccharide and hexasaccharide, or chondroitin-4-sulfate tetrasacharide, X-ray diffraction structure determination and analysis at 1.7-1.8 A resolution, modeling of substrate binding in the active site groove
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
E243A
site-directed mutagenesis, Ca2+-binding residue, about 3.6fold reduced activity compared to the wild-type enzyme
E243A/E245A
site-directed mutagenesis, Ca2+-binding residue, about 4fold reduced activity compared to the wild-type enzyme
E245A
site-directed mutagenesis, Ca2+-binding residue, about 6fold reduced activity compared to the wild-type enzyme
E333A
PCR site-directed mutagenesis, E333 is a key residue in catalysis, reduced activity
H272A
PCR site-directed mutagenesis, H272 is a key residue in catalysis, reduced activity
K250A
PCR site-directed mutagenesis, inactive mutant
N213Q
site-directed mutagenesis, Ca2+-binding residue, about 6fold reduced activity compared to the wild-type enzyme
R271A
PCR site-directed mutagenesis, R271 is a key residue in catalysis
R271E
site-directed mutagenesis, active site mutant, catalytically inactive
R271K
site-directed mutagenesis, active site mutant, about 10fold reduced activity compared to the wild-type enzyme
R363A
PCR site-directed mutagenesis, R363 is a key residue in catalysis, 2fold increased activity
R364A
PCR site-directed mutagenesis, highly reduced activity, altered product profil, residue is involved in determination of substrate specificity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Gu, K.; Linhardt, R.L.; Laliberte, M.; Gu, K.; Zimmermann, J.
Purification, characterization and specificity of chondroitin lyases and glycuronidase from Flavobacterium heparinum
Biochem. J.
312
569-577
1995
Pedobacter heparinus
brenda
Li, Y.; Matte, A.; Su, H.; Cygler, M.
Crystallization and preliminary X-ray analysis of chondroitinase B from Flavobacterium heparinum
Acta Crystallogr. Sect. D
55
1055-1057
1999
Pedobacter heparinus (Q46079), Pedobacter heparinus
brenda
Tkalec, A.L.; Fink, D.; Blain, F.; Zhang-Sun, G.; Laliberte, M.; Bennett, D.C.; Gu, K.; Zimmermann, J.J.F.; Su, H.
Isolation and expression in Escherichia coli of cslA and cslB, genes coding for the chondroitin sulfate-degrading enzymes chondroitinase AC and chondroitinase B, respectively, from Flavobacterium heparinum
Appl. Environ. Microbiol.
66
29-35
2000
Pedobacter heparinus (Q46079), Pedobacter heparinus
brenda
Pojasek, K.; Shriver, Z.; Kiley, P.; Venkataraman, G.; Sasisekharan, R.
Recombinant expression, purification, and kinetic characterization of chondroitinase AC and chondroitinase B from Flavobacterium heparinum
Biochem. Biophys. Res. Commun.
286
343-351
2001
Pedobacter heparinus (Q46079), Pedobacter heparinus
brenda
Ototani, N.; Yosizawa, Z.
Purification of chondroitinase B and chondroitinase C using glycosaminoglycan-bound AH-Sepharose 4B
Carbohydr. Res.
70
295-306
1979
Pedobacter heparinus
brenda
Denholm, E.M.; Lin, Y.Q.; Silver, P.J.
Anti-tumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation and invasion
Eur. J. Pharmacol.
416
213-221
2001
Homo sapiens
brenda
Pojasek, K.; Raman, R.; Kiley, P.; Venkataraman, G.; Sasisekharan, R.
Biochemical characterization of the chondroitinase B active site
J. Biol. Chem.
277
31179-31186
2002
Pedobacter heparinus (Q46079), Pedobacter heparinus
brenda
Michel, G.; Pojasek, K.; Li, Y.; Sulea, T.; Linhardt, R.J.; Raman, R.; Prabhakar, V.; Sasisekharan, R.; Cygler, M.
The structure of chondroitin B lyase complexed with glycosaminoglycan oligosaccharides unravels a calcium-dependent catalytic machinery
J. Biol. Chem.
279
32882-32896
2004
Pedobacter heparinus (Q46079), Pedobacter heparinus
brenda
Suzuki, K.; Terasaki, Y.; Uyeda, M.
Inhibition of hyaluronidases and chondroitinases by fatty acids
J. Enzyme Inhib. Med. Chem.
17
183-186
2002
Pedobacter heparinus (Q46079)
brenda
Huang, W.; Matte, A.; Li, Y.; Kim, Y.S.; Linhardt, R.J.; Su, H.; Cygler, M.
Crystal structure of chondroitinase B from Flavobacterium heparinum and its complex with a disaccharide product at 1.7 A resolution
J. Mol. Biol.
294
1257-1269
1999
Pedobacter heparinus (Q46079), Pedobacter heparinus
brenda
Makovitzky, J.; Richter, S.; Appel, T.R.
Topooptical investigations and enzymatic digestions on tissue-isolated amyloid fibrils
Acta Histochem.
108
193-196
2006
Pedobacter heparinus
brenda
Oguma, T.; Tomatsu, S.; Montano, A.M.; Okazaki, O.
Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry
Anal. Biochem.
368
79-86
2007
Pedobacter heparinus
brenda
Nakamura, H.; Shim, J.; Butz, F.; Aita, H.; Gupta, V.; Ogawa, T.
Glycosaminoglycan degradation reduces mineralized tissue-titanium interfacial strength
J. Biomed. Mater. Res. A
77
478-486
2006
Pedobacter heparinus
brenda
Volpi, N.; Maccari, F.
Structural characterization and antithrombin activity of dermatan sulfate purified from marine clam Scapharca inaequivalvis
Glycobiology
19
356-367
2008
Pedobacter heparinus (Q46079), Pedobacter heparinus
brenda
Wu, J.; Ji, Y.; Su, N.; Li, Y.; Liu, X.; Mei, X.; Zhou, Q.; Zhang, C.; Xing, X.H.
Establishment of chondroitin B lyase-based analytical methods for sensitive and quantitative detection of dermatan sulfate in heparin
Carbohydr. Polym.
144
338-345
2016
Pedobacter heparinus (Q46079), Pedobacter heparinus DSM 2366 (Q46079)
brenda